Symptomatic tumor progression was suspected in 2018, leading to a surgical tumor biopsy that demonstrated WHO grade 4 <i>IDH1</i> and <i>IDH2</i> mutant diffuse astrocytoma. This evidence concerns the gene IDH2 and diffuse astrocytoma.